Building on more than two decades of trusted collaboration in pharmaceutical APIs, this strategic partnership marks a significant new milestone in the relationship between the two companies. It is founded on mutual trust, reliable cooperation, shared quality standards and a strong commitment to serving the pharmaceutical industry.

As a highly respected German manufacturer, CHEMISCHE FABRIK BERG offers extensive expertise in the GMP-compliant production of active pharmaceutical ingredients (APIs), controlled substances, and advanced intermediates. Its strong regulatory track record, manufacturing excellence, and commitment to the highest quality standards make it a trusted partner for pharmaceutical companies worldwide.

Over the past two decades, WELDING PHARMA API and CHEMISCHE FABRIK BERG have successfully collaborated on numerous projects, consistently delivering dependable supply chains, technical expertise, and customer-focused solutions. The exclusive partnership for Lisdexamfetamine dimesilate further strengthens this proven alliance and reflects the shared ambition of both companies to support the evolving needs of the global pharmaceutical market.

With growing demand for innovative ADHD treatments, Lisdexamfetamine dimesilate represents an important addition to the therapeutic landscape. Alongside well-established APIs such as Methylphenidate and Dexamfetamine, it offers pharmaceutical companies a valuable next-generation option for the development of differentiated treatment solutions.

Through this exclusive partnership, WELDING PHARMA API and CHEMISCHE FABRIK BERG provide customers with comprehensive expertise covering product development, manufacturing, regulatory requirements, and market access. Together, the partners offer a reliable foundation for successful and sustainable pharmaceutical projects in the ADHD segment.

“We are delighted to expand our long-standing partnership with CHEMISCHE FABRIK BERG through this exclusive collaboration for Lisdexamfetamine dimesilate. Our companies have worked side by side for more than 20 years, united by a shared commitment to quality, technical excellence, reliability, and customer success. This new project further reinforces our ability to provide pharmaceutical companies with trusted supply solutions and expert support in a growing and strategically important market.” says Oliver Sternhagen, Head of Sales, WELDING PHARMA API.

WELDING PHARMA API will showcase Lisdexamfetamine dimesilate alongside its comprehensive portfolio of active pharmaceutical ingredients at CPhI Milan 2026, taking place from 6-8 October 2026. Visitors are warmly invited to meet the team at Booth 5A81 to explore opportunities related to Lisdexamfetamine dimesilate, discuss the broader API portfolio, and discover tailored solutions for their specific development and sourcing requirements.

For further information, partnership discussions, or media inquiries, please contact the WELDING PHARMA API team via the dedicated contact form: https://welding.eu/en/contact/contact-form-pharma-api/